Zahra Razavi1, Saba Maher2, Javad Fredmal3. 1. Associate Professor, Pediatric Endocrinologist, Pediatrics Department, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran. razavizahra@yahoo.com.au. 2. Pediatric Senior Resident, Department of Pediatrics, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran. 3. Associate Professor of Biostatistics, Hamedan University of Medical Sciences, Hamedan, Iran.
Abstract
PURPOSE: To compare the safety/efficacy of intermittent subcutaneous rapid-acting insulin aspart with the standard low-dose intravenous infusion protocol of regular insulin for treatment of pediatric diabetic-ketoacidosis. METHODS: For a prospective randomized-controlled clinical trial on 50 children/adolescents with mild/moderate diabetic-ketoacidosis, the diagnostic criteria for ketoacidosis included: blood glucose level >250 mg/dl, ketonuria>++, venous pH <7.3 and/or bicarbonate <15 mEq/l. DATA COLLECTED: age, sex, clinical/laboratory parameters including blood sugar, arterial blood gases, urine ketones, severity of diabetic-ketoacidosis, amount of insulin administered to correct acidosis, time to recover from diabetic-ketoacidosis, number of days of hospitalization, and complications. Patients were randomly assigned to intervention (subcutaneous) and control (intravenous) groups. Controls received 0.05-0.1 unit/kg/hour intravenous regular insulin infusion until resolution of diabetic-ketoacidosis and stayed in the intensive care unit. Interventions received 0.15 unit/kg subcutaneous insulin aspart every two hours and stayed in regular medical ward. RESULTS:From 50 children (age 2-17 years), 56% (28) were females, and 48% (24) had established-type I diabetes. Intervention and control groups had similar baseline clinical/laboratory findings. Average age (years) was 8.6 ± 0.8 for intervention and 8.86 ± 0.7 for control group (p = 0.4) with 64% having moderate diabetic-ketoacidosis. The mean total-dose of insulin units needed for treatment of diabetic-ketoacidosis in intervention (subcutaneous insulin aspart) was lower than controls (intravenous regular insulin) (p < 0.001). No mortality/serious events happened. Three diabetic-ketoacidosis recurrences among interventions and one among controls occurred. CONCLUSIONS: To manage mild/moderate diabetic-ketoacidosis in children/adolescents, subcutaneous rapid-acting insulin aspart is an alternative to intravenous infusion of regular insulin. Subcutaneous insulin treated moderate DKA with faster recovery/shorter hospital stay.
RCT Entities:
PURPOSE: To compare the safety/efficacy of intermittent subcutaneous rapid-acting insulinaspart with the standard low-dose intravenous infusion protocol of regular insulin for treatment of pediatric diabetic-ketoacidosis. METHODS: For a prospective randomized-controlled clinical trial on 50 children/adolescents with mild/moderate diabetic-ketoacidosis, the diagnostic criteria for ketoacidosis included: blood glucose level >250 mg/dl, ketonuria>++, venous pH <7.3 and/or bicarbonate <15 mEq/l. DATA COLLECTED: age, sex, clinical/laboratory parameters including blood sugar, arterial blood gases, urine ketones, severity of diabetic-ketoacidosis, amount of insulin administered to correct acidosis, time to recover from diabetic-ketoacidosis, number of days of hospitalization, and complications. Patients were randomly assigned to intervention (subcutaneous) and control (intravenous) groups. Controls received 0.05-0.1 unit/kg/hour intravenous regular insulin infusion until resolution of diabetic-ketoacidosis and stayed in the intensive care unit. Interventions received 0.15 unit/kg subcutaneous insulinaspart every two hours and stayed in regular medical ward. RESULTS: From 50 children (age 2-17 years), 56% (28) were females, and 48% (24) had established-type I diabetes. Intervention and control groups had similar baseline clinical/laboratory findings. Average age (years) was 8.6 ± 0.8 for intervention and 8.86 ± 0.7 for control group (p = 0.4) with 64% having moderate diabetic-ketoacidosis. The mean total-dose of insulin units needed for treatment of diabetic-ketoacidosis in intervention (subcutaneous insulinaspart) was lower than controls (intravenous regular insulin) (p < 0.001). No mortality/serious events happened. Three diabetic-ketoacidosis recurrences among interventions and one among controls occurred. CONCLUSIONS: To manage mild/moderate diabetic-ketoacidosis in children/adolescents, subcutaneous rapid-acting insulinaspart is an alternative to intravenous infusion of regular insulin. Subcutaneous insulin treated moderate DKA with faster recovery/shorter hospital stay.
Authors: Thais Della Manna; Leandra Steinmetz; Paula R Campos; Sylvia C L Farhat; Cláudio Schvartsman; Hilton Kuperman; Nuvarte Setian; Durval Damiani Journal: Diabetes Care Date: 2005-08 Impact factor: 19.112
Authors: Guillermo E Umpierrez; Kashif Latif; James Stoever; Ruben Cuervo; Linda Park; Amado X Freire; Abbas E Kitabchi Journal: Am J Med Date: 2004-09-01 Impact factor: 4.965
Authors: Guillermo E Umpierrez; Ruben Cuervo; Ana Karabell; Kashif Latif; Amado X Freire; Abbas E Kitabchi Journal: Diabetes Care Date: 2004-08 Impact factor: 19.112
Authors: Carlos A Andrade-Castellanos; Luis Enrique Colunga-Lozano; Netzahualpilli Delgado-Figueroa; Daniel A Gonzalez-Padilla Journal: Cochrane Database Syst Rev Date: 2016-01-21
Authors: Ibrahim Abdulaziz Bali; Muneera Rashid Al-Jelaify; Yazed AlRuthia; Jaazeel Zohair Mulla; Dana Fawzi Amlih; Alanoud Ibrahim Bin Omair; Reem Abdullah Al Khalifah Journal: JAMA Netw Open Date: 2022-09-01